Elevian will commercialise research from Harvard and Stanford indicating young blood cells could be used to restore tissues in older patients.

Elevian, a US-based regenerative medicine developer based on research from Harvard and Stanford universities, has made its public debut with $5.5m in seed capital from investors including Stanford-StartX Fund. Bold Capital Partners, Longevity Fund, Western Technology Investment, Kizoo Technology Ventures, Thynk Capital and unnamed additional investors have contributed to the round. Founded in 2017, Elevian will commercialise a therapy for age-related diseases such as coronary artery disease and Alzheimer’s based on the principle that inserting young blood cells into an older patient may have a regenerative effect. The company is focusing on a circulation factor called GDF11 that it has linked to the repair of tissues in the heart, brain and muscles. Elevian builds on research on mice conducted at Harvard and then Stanford by researchers including Manisha Sinha, a former post-doctoral scientist at Harvard Stem Cell and Regenerative Biology who is now head of cell biology at Elevian. Mark Allen, co-founder and chief executive of Elevian, said: “By therapeutically targeting a fundamental mechanism of aging, it may be possible to treat and prevent many diseases of aging with a single drug.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?